It is thought that IMCA may be a specific antagonist of NR4A1 through the NR4A1 and SESN/AMPK/mTOR signaling pathway and therefore can be used in the treatment of thyroid carcinomas. This evidence concerns the gene NR4A1 and thyroid gland carcinoma.